The percentage of participants who had weight reduction of 5% or more was 85%, 89%, and 91% with 5 mg, 10 mg, and 15 mg of tirzepatide , respectively, and 35% with placebo
To evaluate inter-study statistical heterogeneity, we calculated I2 parameters, with values exceeding 50% indicative of noteworthy heterogeneity
10.1016/j.phrs.2017.10.013 73 ZhouH.WangS.ZhuP.HuS.ChenY.RenJ
Most of this weight loss occurs in the first 32 weeks
Moreover, its benefits vary, and safety (especially when it comes to IV use) is uncertain and concerning
Monitoring remains as fresh data emerges